Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
05/08/26	$0.4666	+1.43%	121,302
04/08/26	$0.4600	+3.00%	125,687
03/08/26	$0.4466	-2.89%	341,974
31/07/26	$0.4599	+3.58%	252,862
30/07/26	$0.4440	-1.33%	572,243

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4600USD

Average target price

3.000USD

Spread / Average Target

+552.17%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 21:37:38 05/08/2026 +03			5-day change	1st Jan Change
0.4660 ^USD	+1.30%		+3.69%	-63.83%

06-30	Pasithea Therapeutics Reports Positive Interim Phase 1 Advanced Cancer Study Data And Protocol Expansion	CI
06-30	Pasithea Therapeutics Says Interim Phase 1 Data for PAS-004 Show Durable Clinical Activity	MT

Market Cap	15.37M 13.31M 12.41M 11.41M 21.55M 1.46B 21.79M 146M 57.24M 731M 57.73M 56.46M 2.42B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	15.37M 13.31M 12.41M 11.41M 21.55M 1.46B 21.79M 146M 57.24M 731M 57.73M 56.46M 2.42B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	98.89%	Yield 2026 *	-	Yield 2027 *	-

06-30	Pasithea Therapeutics Reports Positive Interim Phase 1 Advanced Cancer Study Data And Protocol Expansion	CI
06-30	Pasithea Therapeutics Says Interim Phase 1 Data for PAS-004 Show Durable Clinical Activity	MT
06-16	Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment	MT
06-16	Pasithea Therapeutics Amends Clinical Study Protocol for Phase 1/1B Nf1 Clinical Trial	CI
06-02	Pasithea Therapeutics Gets US FDA Orphan Drug Status for ALS Candidate	MT
05-15	Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	Pasithea Therapeutics Corp. Appoints Kartik Krishnan as Chief Medical Officer, Effective May 1, 2026	CI
04-20	Pasithea Therapeutics Corp Announces Grant of Rare Pediatric Disease Designation by FDA to Pas-004 for Treatment of Neurofibromatosis Type 1	CI
04-01	Pasithea Therapeutics Corp Announces Grant of Fast Track Designation by Fda to Pas-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity	CI
03-31	Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-03	Certain Pre-Funded warrants of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026.	CI
03-03	Certain Warrants of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026.	CI
03-03	Certain Options of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026.	CI

12-08	HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target	MT
03/04/23	EF Hutton Adjusts Price Target on Pasithea Therapeutics to $2 From $2.30, Maintains Buy Rating	MT

Pasithea Therapeutics Corp. Stock

Stocks

KTTA

US70261F2020

Biotechnology & Medical Research

Valuation: Pasithea Therapeutics Corp.

Chart: Pasithea Therapeutics Corp.

Latest news : Pasithea Therapeutics Corp.

Last Transcript: Pasithea Therapeutics Corp.

Analysts' recommendations: Pasithea Therapeutics Corp.

Press Releases: Pasithea Therapeutics Corp.

Quotes and Performance

Course Extremes

Managers and Directors: Pasithea Therapeutics Corp.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-21	Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026	AQ
07-08	Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit	AQ
06-30	Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion	AQ
06-16	Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial	AQ
06-15	Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference	AQ

1 day	+1.52%
1 week	+3.69%
Current month	+1.46%
1 month	-10.27%
3 months	-45.11%
6 months	-38.74%
Current year	-63.83%

1 week	0.43	0.49
1 month	0.42	0.56
Current year	0.42	1.28
1 year	0.28	2.06
3 years	0.28	17.4
5 years	0.28	170
10 years	0.28	170

Manager	Title	Age	Since
Tiago Marques CEO	Chief Executive Officer	49	01/08/2020
Daniel Schneiderman DFI	Director of Finance/CFO	48	11/10/2022
Kartik Krishnan CTO	Chief Tech/Sci/R&D Officer	55	01/05/2026

Director	Title	Age	Since
Lawrence Steinman CHM	Chairman	78	-
Tiago Marques BRD	Director/Board Member	49	01/08/2020
Simon Dumesnil BRD	Director/Board Member	49	01/04/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/28/25 A	Daniel Schneiderman	Free	Chief Financial Officer	26,667	0.3583%
11/28/25 A	Simon Dumesnil	Buy	Director	33,333	0.4478%
11/28/25 A	Lawrence Steinman	Buy	Founder	133,333	1.7912%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PASITHEA THERAPEUTICS CORP.	+1.30%	+3.69%	-32.41%	-96.04%	15.37M
WUXI APPTEC CO., LTD.	+4.35%	+19.90%	+60.59%	+95.21%	62.53B
ARGENX SE	+2.83%	-3.48%	+24.97%	+69.33%	52.43B
BIONTECH SE	-0.28%	-2.02%	-18.01%	-7.54%	23.1B
INSMED INCORPORATED	+1.40%	-2.67%	-10.07%	+358.94%	21.4B
WUXI BIOLOGICS (CAYMAN) INC.	+0.40%	+5.29%	+30.11%	-9.63%	21.17B
GENMAB A/S	+0.75%	+1.34%	+32.22%	-25.54%	17.76B
PHARMAESSENTIA CORPORATION	+9.88%	+19.73%	+229.67%	+385.49%	15.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+2.08%	-3.28%	+21.67%	+564.59%	14.68B
EXELIXIS, INC.	+1.11%	+2.33%	+51.15%	+179.60%	14.08B
Average	+2.43%	+3.51%	+38.99%	+151.44%	24.26B
Weighted average by Cap.	+2.76%	+4.59%	+42.31%	+136.90%

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-